1448525-65-2

Upstream product

• 4530-20-5 BOC-glycine 
• 5509-65-9 2,6-difluoroaniline 
• 18185-77-8 tert-butyloxycarbonylglycine imidazolide 

Downstream Products

• 1040052-95-6 2-amino-N-(2,6-difluorophenyl)acetamide 
• 1632992-09-6 C₈H₈F₂N₂S 
• 1448525-78-7 [(2,6-difluorophenylthiocarbamoyl)methyl]carbamic acid tert-butyl ester 
• 1448524-02-4 2-(4-bromophenoxy)-N-[(2,6-difluorophenylcarbamoyl)methyl]acetamide 
• 1448524-08-0 2-(4-chlorophenoxy)-N-[(2,6-difluorophenylcarbamoyl)methyl]acetamide 
• 1448524-09-1 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-(4-phenoxyphenoxy)acetamide 
• 1448524-10-4 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-m-tolyloxyacetamide 
• 1448524-11-5 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-(4-methoxyphenoxy)acetamide 
• 1448524-12-6 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-(4-fluorophenoxy)acetamide 
• 1448524-13-7 2-(4-bromophenoxy)-N-[(2,6-difluorophenylthiocarbamoyl)methyl]acetamide 
• 1448524-14-8 N-[(2,6-difluorophenylthiocarbamoyl)methyl]-2-(4-methoxyphenoxy)acetamide 
• 1448524-22-8 2-(4-benzyloxyphenoxy)-N-[(2,6-difluorophenylcarbamoyl)methyl]acetamide 
• 1448524-25-1 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-(4-hydroxyphenoxy)acetamide 

Relevant academic research and scientific papers

SERINE RACEMASE INHIBITOR

A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR'_1], [LW_1], and [ED_1] as an active ingredient.

In silico and pharmacological screenings identify novel serine racemase inhibitors

d-Serine is a coagonist of the N-methyl-d-aspartate (NMDA)-type glutamate receptor and its biosynthesis is catalyzed by serine racemase (SR). The overactivation of the NMDA receptor has been implicated in the development of neurodegenerative diseases, strokes, and epileptic seizures, thus, the inhibitors of SR have potential against these pathological states. Here, we have developed novel inhibitors of SR by in silico screening and in vitro enzyme assay. The newly developed inhibitors have lower IC50 value comparing with that of malonate, one of the standard SR inhibitor. The structural features of novel inhibitors suggest the importance of central amide structure having a phenoxy substituent in their structure for the SR inhibitory activity. The present findings suggest the importance and rational development of new drugs for diseases of NMDAR overactivation.